



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za

Ref: **HP04-2020ONC**

HP04-2020ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2020 TO 30 JUNE 2022

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape	Mr C Dlova	(047) 532-5536	mncedisi.dlova@echealth.gov.za
Free State	Ms M Smits	(051) 411-0525	smitsm@fshealth.gov.za
Gauteng	Mr DS Malele	(011) 628-9131	dumisane.malele@gauteng.gov.za
Kwazulu-Natal	MS SB Nhlapo	(035) 901-7004	sibusisiwe.nhlapo@kznhealth.gov.za
Limpopo	Mr TS Rasekele	(015) 223-9065	rassolly@gmail.com
Mpumalanga	Mr T Moralo	(013) 283-9001	tshegofatsom@mpuhealth.gov.za
North West	Mr M Gutta	(018) 384-4838	mgutta@nwpg.gov.za
Northern Cape	Ms E Delport	(053) 830-2717	edelport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za

K Jamaloodien

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
For: DIRECTOR-GENERAL: HEALTH
DATE: 14/5/2020

(PAGE 2)

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Adcock Ingram Critical Care (Pty) Ltd	V4222	MAAA0010153	P O Box 6888 JOHANNESBURG 2000	Petunia Motlhako	(011) 494-8129	petunia.motlhako@adcock.com
Astellas Pharma (Pty) Ltd	V0L15	MAAA0006887	P O Box 2446 BEDFORDVIEW 2008	Derek Haynes	(011) 615-9433 (083) 269-4688	derek.haynes@za.astellas.com
AstraZeneca Pharmaceuticals (Pty) Ltd	V2180	MAAA0006577	Private Bag X23 BRYANSTON 2021	Sihesenkosi Mncube	(011) 797-6000 (083) 557-3824	sihesenkosi.mncube@astrazeneca.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Biotech Laboratories (Pty) Ltd	VUV35	MAAA0029826	Suite 150 Private Bag X65 HALFWAY HOUSE 1685	Mandy Burststein	(011) 848-3050 (083) 285-8699	tenders@biotechlabs.co.za
Fresenius Medical Care SA (Pty) Ltd	V2A97	MAAA0088919	Private Bag X10039 EDENVALE 1610	Erlene Brisset	(011) 457-9353 (066) 298-0533	erlene.brisset@fmc-ag.com
Key Oncologics (Pty) Ltd	VAYM6	MAAA0009144	Postnet Suite 19 P O Box 92418 NORWOOD 2117	Margaretha De Wet	(011) 483-0060 (082) 567-5197	magriet@keyoncologics.co.za
Litha Pharma (Pty) Ltd	VGS73	MAAA0009244	P O Box 8356 MIDRAND 1685	Trevor Reddy	(011) 516-1785 (066) 304-6900	trevor.reddy@acino.swiss
Mylan (Pty) Ltd	V3PS6	MAAA0081441	Postnet Suite #23 Private Bag X10010 EDENVALE 1610	Kumaraswamy Ekhambaram	(011) 451-1300 (071) 473-3900	kumaraswamy.ekhambaram@mylan.in
Novartis SA (Pty) Ltd	VBVW2	MAAA0006317	Novartis Building Magwa Crescent West Waterfall City JUKSKEI VIEW 2090	Fareeya Vahed / Kumeshnie Padayachee	(011) 347-6645 (083) 997-3131	fareeya.vahed@novartis.com kumeshnie.padayachee@novartis.com
Pfizer Laboratories (Pty) Ltd	V2189	MAAA0019202	P O Box 783720 SANDTON 2000	Themba Mnguni	(011) 320-6091 (082) 307-9658	themba.mnguni@pfizer.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Pharmacare Limited	V2205	MAAA0008452	P O Box 1593 GALLO MANOR 2052	Itumeleng Mathe	(011) 239-6243 (083) 298-4336	imathe@aspenpharma.com
Pharmaco Distribution (Pty) Ltd	VBVW1	MAAA0044115	P O Box 786522 SANDTON 2146	Jan van den Berg	(011) 784-0077 (082) 572-7832	jan.vandenberg@pharmaco.co.za
Ranbaxy Pharmaceuticals (Pty) Ltd	V4728	MAAA0000384	P O Box 43486 INDUSTRIA 2042	Deepakh Mangal Sewnarain	(012) 643-2000 (082) 893-8649	deepakh.sewnarain@sunpharma.com
Sandoz SA (Pty) Ltd	VVZ69	MAAA0011663	P O Box 154 ISANDO 1600	Renee Moodley	(011) 929-9002 (083) 704-1806	renee.moodley@sandoz.com
Sanofi-Aventis SA (Pty) Ltd	V2160	MAAA0009069	Private Bag X207 MIDRAND 1685	Jaidev Maharaj	(011) 847-5264 (082) 943-3952	jaidev.maharaj@sanofi.com
Teva Pharmaceuticals (Pty) Ltd	V43G1	MAAA0842904	P O Box 1590 RUIMSIG 1732	Judy Klinkradt	(011) 055-0200 (082) 771-3513	judy.klinkradt@teva.co.za

Item No	Item Specification	Quantity Awarded	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (± 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
3	Antithymocyte immunoglobulin (Rabbit) 100mg injection	770	Fresenius Medical Care SA (Pty) Ltd	MAAA0008919	V2A97	ATG Fresenius S	R4,424.74	1 x 5ml	5	5	90.00	180327500	VI
5	Azathioprine 50mg tablet, 100 tablets	76,124	Litha Pharma (Pty) Ltd	MAAA0009244	VGS73	Azatumun 50mg Tablets	R94.23	1 x 100	14	50	96.00	189710268	CO
9	Busulfan 2mg tablet, 100 tablets	277	Pharmacare Limited	MAAA0008452	V2205	MYLERAN 2MG TAB 100	R1,201.23	1 x 100	14	1	90.00	189710642	CO
10	Calcium Folate equivalent to Folic Acid 15mg tablet, 10 tablets	5,880	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	RescuvoLin 15 mg Tabs	R222.39	1 x 10	14	5	90.00	189711671	CO
19	Chlorambucil 2mg tablet, 25 tablets	6,022	Pharmacare Limited	MAAA0008452	V2205	LEUKERAN 2MG TABS 25S	R415.60	1 x 25	14	3	90.00	189710834	CO
20	Ciclosporin 100mg capsule, 50 capsules Items 21 and 20 will be considered as a series	15,270	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 100mg	R760.73	1 x 50	14	1	91.00	180001233	CO
21	Ciclosporin 25mg capsule, 50 capsules Items 20 and 21 will be considered as a series	30,840	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 25mg	R190.33	1 x 50	14	1	91.00	180001218	CO
22	Ciclosporin 100mg/ml oral solution, 50ml	1,265	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 100mg/ml	R909.53	1 x 1	14	1	91.00	189712364	VI
23	Ciclosporin 50mg injection	16,450	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandimmun Neoral 50mg injection	R60.08	1 x 10	14	1	91.00	180073825	AM
34	Docetaxel 20mg injection Items 35 and 34 will be considered as a series	8,832	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	Docetere RTU 20mg 1's	R287.04	1 x 1	14	1	91.00	180182958	VI
35	Docetaxel 80mg injection Items 34 and 35 will be considered as a series	38,780	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	Docetere RTU 80mg 1's	R681.72	1 x 1	14	10	91.00	180182961	VI
41	Everolimus 0.25mg tablet, 60 tablets Items 42 and 41 will be considered as a series	477	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Certican 0.25mg	R609.52	1 x 60	14	1	91.00	181807552	CO
42	Everolimus 0.75mg tablet, 60 tablets Items 41 and 42 will be considered as a series	912	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Certican 0.75	R1,828.50	1 x 60	14	1	91.00	181810492	CO
43	Exemestane 25mg tablet, 28 tablets Pack size offered 30 Tablets	21,700	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	AROMASIN 25MG	R205.29	1 x 30	14	1	91.00	181785231	CO
44	Filgrastim 30MU pre-filled syringe	96,992	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Filgrastim Teva 30MIU 5	R327.70	1 x 5	14	5	90.00	181747103	SG
45	Filgrastim 48MU pre-filled syringe	11,280	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Filgrastim Teva 48MIU 5	R506.57	1 x 5	14	5	90.00	180954695	SG
46	Fludarabine 10mg tablet, 20 tablets	138	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	Fludara 10mg Oral Tabs 20's	R4,140.00	1 x 20	14	1	91.00	181840965	CO
47	Fludarabine Phosphate 50mg injection	2,207	Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	Fludara IV 50mg INJ Soln 5's	R565.11	1 x 5	14	1	91.00	180221925	VI
48	Fluorouracil 5% ointment, 20g	12,791	Mylan (Pty) Ltd	MAAA0081441	V3PS6	Etudix	R659.00	1 x 1	14	20	92.00	180166914	TU
53	Goserelin 3.6mg injection	11,353	AstraZeneca Pharmaceuticals (Pty) Ltd	MAAA0006577	V2180	Zoladex 3.6mg	R455.40	1 x safe system syringe	10	1	90.00	189709944	SG
56	Granisetron 3mg injection	9,700	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	Adco Granisetron 3MG	R48.88	1 x 5	14	5	96.00	180073795	AM
64	Imatinib 400mg tablet/capsule, 30 tablets/capsules	3,823	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Summatin 400	R330.63	1 x 30	14	10	93.00	181823721	CO

Item No	Item Specification	Quantity Awarded	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (± 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
68	Interferon Beta-1a Injection containing 6M IU per ml after reconstitution, injection	366	Litha Pharma (Pty) Ltd	MAAA0009244	VGS73	Avonex Pre Filled Syringe 1x4ml	R4,547.54	1 x 4	14	1 box of 4	96.00	181810858	VI
70	irinotecan 100mg injection	8,532	Mylan (Pty) Ltd	MAAA0081441	V3PS6	Mylan Irinotecan 100 mg / 5ml	R175.24	1 x 1	14	20	92.00	180281234	VI
71	Irinotecan 40mg injection	1,382	Mylan (Pty) Ltd	MAAA0081441	V3PS6	Mylan Irinotecan 40 mg / 2ml	R99.00	1 x 1	14	20	92.00	180347574	VI
73	Medroxyprogesterone Acetate 100mg tablet, 100 tablets	580	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	PROVERA 100MG	R744.26	1 x 100	14	1	91.00	189711677	CO
76	Mercaptopurine 50mg tablet, 25 tablets	10,744	Pharmcare Limited	MAAA0008452	V2205	PURINETHOL 50MG TABS 25'S	R1,065.58	1 x 25	14	1	90.00	189710669	CO
78	Methotrexate 1g injection	24,700	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate 1000mg/10ml	R292.40	1 x 1	14	5	90.00	189715286	VI
79	Methotrexate 2.5mg tablet, 100 tablets	157,299	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate 2.5mg Tabs	R95.80	1 x 100	14	5	90.00	189752683	CO
82	Methotrexate 5g injection	1,520	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Abitrexate-5G 50ml	R1,181.53	1 x 1	14	2	90.00	189714911	VI
83	Mitoxantrone 20mg injection	1,260	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Mitoxantrone Hexal 20mg /10ml Inj	R2,564.33	1 x 1	14	10	90.00	189712326	VI
85	Mycophenolate mofetil 250mg capsule, 100 capsules Items 86 and 85 will be considered as a series	41,800	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Mycoccept 250mg Caps	R230.00	1 x 100	14	50	90.00	180300085	CO
86	Mycophenolate mofetil 500mg tablet, 50 tablets Items 85 and 86 will be considered as a series	39,050	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Mycoccept 500mg Tabs	R230.00	1 x 50	14	50	90.00	181820031	CO
87	Mycophenolic acid 180mg tablet, 120 tablets Items 88 and 87 will be considered as a series	1,780	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Myfortic 180	R806.74	1 x 120	14	1	91.00	181835259	CO
88	Mycophenolic acid 360mg tablet, 120 tablets Items 87 and 88 will be considered as a series	1,851	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Myfortic 360	R1,085.73	1 x 120	14	1	91.00	181813273	CO
89	Nilotinib 200mg capsule, 112 capsules	2,160	Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Tasigna 200mg	R2,256.22	1 x 112	14	1	91.00	181866360	CO
90	Ondansetron 4mg dispersible tablet, 10 tablets	45,100	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Zofer Reptiab 4	R6.15	1 x 10	14	50	93.00	180954155	CO
91	Ondansetron 4mg injection	168,370	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ONDANSETRON HEXAL 4 mg INJECTION	R2.39	1 x 5 amp	14	5	95.00	180073817	AM
92	Ondansetron 8mg injection	244,970	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ONDANSETRON HEXAL 8 mg INJECTION	R4.19	1 x 5 amp	14	5	95.00	180073819	AM
93	Ondansetron 8mg tablet, 10 tablets	46,940	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Zofer 8	R6.89	1 x 10	14	50	93.00	181858255	CO
94	Oxaliplatin 100mg injection Items 95 and 94 will be considered as a series	15,820	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Oxaliplatin PCH 100 mg/20 ml Conc	R248.68	1 x 1	14	5	90.00	181804652	VI
95	Oxaliplatin 50mg injection Items 94 and 95 will be considered as a series	10,382	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Oxaliplatin PCH 50 mg/10 ml Conc	R179.87	1 x 1	14	5	90.00	181804649	VI
101	Stromilium 1mg tablet, 30 tablets	6,940	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	RAPAMUNE 1MG	R2,163.18	1 x 30	14	1	91.00	181756276	CO
102	Tacrolimus 0.5mg capsules, 30 capsules Items 103, 104 and 102 will be considered as a series	8,240	Astellas Pharma (Pty) Ltd	MAAA0006887	VOL15	Prograf 0.5mg	R151.80	1 x 30	14	1	93.00	222000430	CO
103	Tacrolimus 1mg capsule, 30 capsules Items 104, 102 and 103 will be considered as a series	51,375	Astellas Pharma (Pty) Ltd	MAAA0006887	VOL15	Prograf 1mg	R301.30	1 x 30	14	1	93.00	222000431	CO

Item No	Item Specification	Quantity Awarded	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price in ZAR	Pack Size Offered: Unit Pack	Lead-Time (± 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
104	Tacrolimus 5mg capsule, 30 capsules Items 102, 103 and 104 will be considered as a series	10,180	Astellas Pharma (Pty) Ltd	MAAA0006887	VOL15	Prograf 5mg	R1,488.10	1 x 30	14	1	93.00	222000432	CO
106	Thalidomide 50mg capsule, 28 capsules	5,000	Key Oncologies (Pty) Ltd	MAAA0009144	VAYM6	Thalidomide Celgene 50 mg	R1,484.08	1 x 28 capsules / pack	2	2	90.00	181809032	CO
107	Thioguanine 40mg tablet, 25 tablets	1,555	Pharmacare Limited	MAAA0008452	VZ205	LANVIS 40MG TABS 25'S	R2,304.31	1 x 25	14	1	90.00	189712247	CO
108	Trastuzumab 440mg injection	1,952	Mylan (Pty) Ltd	MAAA0081441	V3PS6	Ogivri 440	R4,950.00	1 x 1	14	2	92.00	181776294	VI
109	Tretinoin 10mg capsule, 100 capsules	1,236	Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	Vesancoid 10mg Capsules	R3,968.86	1 x 100	14	2	90.00	180187764	CO
110	Vinblastine 10mg injection	10,865	Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Vinblastine Teva 10 ml	R250.47	1 x 1	14	5	90.00	180969693	VI
113	Vinorelbine 10mg injection Items 114 and 113 will be considered as a series	3,010	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Sandoz Vinorelbine 10mg/1ml	R151.27	1 x 1	14	10	90.00	180221922	VI
114	Vinorelbine 50mg injection Items 113 and 114 will be considered as a series	4,490	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Sandoz Vinorelbine 50mg/5ml	R544.78	1 x 1	14	10	90.00	180221924	VI
115	Zoledronic Acid 4mg injection	23,240	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	Zobone	R158.99	1 x 1	14	20	93.00	181844609	VI



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP04-2020ONC

**SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE
DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2020 TO 30 JUNE 2022**

BID VALIDITY PERIOD: 120 DAYS

CLOSING DATE AND TIME OF BID:

28 OCTOBER 2019 AT 11h00

NON-COMPULSORY BRIEFING SESSION:

**VENUE: NATIONAL DEPARTMENT OF HEALTH, IMPILO BOARDROOM, PODIUM
LEVEL, CIVITAS BUILDING, C/O THABO SEHUME AND STRUBEN
STREETS, PRETORIA, 0002**

TIME: 10:00

DATE: 8 OCTOBER 2019



TABLE OF CONTENTS

ABBREVIATIONS	4
BID DOCUMENT CHECK LIST	5
SECTION A	8
1. LEGISLATIVE AND REGULATORY FRAMEWORK	8
2. BID INFORMATION SESSION	8
3. EVALUATION CRITERIA	8
3.1 PHASE I: MANDATORY REQUIREMENTS	9
3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID.....	9
3.1.2 RESPONSIVE BIDS.....	10
3.1.3 BID DOCUMENTS.....	10
3.1.4 AUTHORISATION DECLARATION.....	11
3.1.5 TAX COMPLIANCE STATUS.....	11
4. PHASE II: PRODUCT TECHNICAL COMPLIANCE	12
4.1.1 SAMPLES TO BE SUBMITTED TO HEALTH ENTITIES.....	12
4.1.2 COMPLIANCE WITH SPECIFICATIONS.....	13
5. PHASE IV: PREFERENCE POINT SYSTEM	14
5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:	14
5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR	14
6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	15
7. VALUE ADDED TAX	16
8. SUBMISSION OF BIDS	17
9. COMPLETION OF DOCUMENTS AND BID SUBMISSION	18
10. LATE BIDS	19
11. COUNTER CONDITIONS	20
12. FRONTING	20
13. SUPPLIER DUE DILIGENCE	20
14. COMMUNICATION	21
15. CONTACT DETAILS	21
SECTION B	22
16. CONTRACT PERIOD	22
17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS	22
18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	22
19. POST AWARD PARTICIPATION	23
20. AWARD CONDITIONS	23
20.1 SPLIT AND MULTIPLE AWARDS.....	24
20.2 THERAPEUTIC CLASS AWARDS.....	25



21. NEGOTIATIONS	26
22. NON-COMMITMENT	26
23. PRICE REVIEW	26
23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS	27
23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN	27
23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK	27
23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS	28
23.4 ROUTINE PRICE ADJUSTMENTS	29
23.5 EXCEPTIONAL PRICE ADJUSTMENTS	29
23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	30
24. QUALITY	30
25. DELIVERY AND QUANTITIES	30
25.1 DELIVERY BASIS	30
25.2 QUANTITIES	31
SECTION C	32
26. SUPPLIER PERFORMANCE MANAGEMENT	32
26.1 Supplier performance management	32
26.2 DELIVERY ADHERENCE	33
26.3 CONTINUITY OF SUPPLY	34
26.4 REPORTING	35
27. PACKAGING, LABELLING AND BARCODES	35
27.1 PACKAGING	35
27.2 LABELLING	36
27.3 BARCODES	37
28. SHELF LIFE	37
29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	38
30. THIRD PARTIES	38



ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax

**BID DOCUMENT CHECK LIST**

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter i.e. limited stock availability of any item offered, non-compliance status relating to TAX, B-BBEE, License to Manufacture, Certificates etc.				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BFI	Bid/File Index				
4	SBD.1	SBD 1: Invitation to bid				
5	PBD4.1	PBD 4.1: Contact Details of Bidder				
6	TCC	Tax Clearance Certificate (Current & Valid)				
7	B-BBEE	Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points				
8	SBD6	SBD 6(1): Preference Points Claimed (B-BBEE)				
9	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
10	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
11	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
12	SBD4	SBD 4: Declaration of interest				



Special Requirements and Conditions of Contract: HP04-2020ONC

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
13	SBD5	SBD5: The National Industrial Participation Programme				
14	SBD8	SBD 8: Declaration of Past SCM Practices				
15	SBD9	SBD 9: Certificate of Independent Bid Determination				
16	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.				
17	PBD1.1	PBD 1.1: List of products offered sourced from third party				
18	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
19	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
20	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.				
21	NC	Proof of company cedings, mergers and name changes				
22	LICMI	Licence to manufacture or import (in the name of the bidder), including all annexures. Certified copies required.				
23	LICM	Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant). Certified copies required.				
24	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.				
25	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order.				



Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
26	PS	Proof of sample submission				
27	BL	Bidder's item list (List of products offered)				
28	PRICE	Signed Excel Bid Response Pricing Schedule All prices <u>must</u> be submitted with two (2) decimals				
All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above						
Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column						

The bid document check list is available as Annexure A in an excel spreadsheet format. All bidders are required to complete and submit in hard copy and the electronic copies as part of "Set 3: Electronic version of bid documents"



SECTION A

1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract (SRCC) are supplementary to General Conditions of Contract (GCC). Where, however, the SRCC are in conflict with the GCC, the SRCC prevail.

2. BID INFORMATION SESSION

A non - compulsory information session will be held.

Date: 08 October 2019

Time: 10H00

Venue: Department of National Health, Impilo Boardroom, Podium Level, Civitas Building, c/o Thabo Sehume and Struben Streets, **PRETORIA**, 0002

It is strongly **recommended** that all prospective bidders attend the information session, which will provide bidders with an opportunity to obtain clarity on the bidding process, the conditions of contract and obtain clarity on any questions that may arise.

3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award



Phase I	Phase II	Phase III	Phase IV
Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award

3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

A certified copy of the Medicine Registration Certificate, issued in terms of section 15(3)(a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1)(b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of such licence must be submitted by the bidder offering the product.



The bidder offering a product must submit a **certified copy** of the licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response. **All prices must be submitted with 2 (two) decimals.** Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The Excel Bid Response Documents i.e pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery. **All prices must be submitted with two (2) decimals.**

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.



Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.

In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.

Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

3.1.5 TAX COMPLIANCE STATUS

The validity of the Tax Clearance Certificate issued by the South African Revenue Services (SARS) certifying that the tax status of the bidder is in order, will be verified against the information recorded in the Central Supplier Database (CSD).



It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the CSD managed by National Treasury. The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database.

Bidders remain responsible for maintaining and updating the CSD information in line with the bid documents submitted for this bid.

4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

4.1.1 SAMPLES TO BE SUBMITTED TO HEALTH ENTITIES

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health entities listed below will invalidate the bid for such items offered.

Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:



Mr Dumisani Malele Depot Manager Tel: 011 628 9131 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001
--	---

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above. Proof of sample submission must be submitted with the bid documents at the closing date and time of the bid.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.

4.1.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.



5. PHASE IV: PREFERENCE POINT SYSTEM

5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

$$P_s = 80 \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right) \quad \text{or} \quad P_s = 90 \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right)$$

Where

- P_s = Points scored for price of bid under consideration
 P_t = Price of bid under consideration
 P_{\min} = Price of lowest acceptable bid

5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

For this tender, the 90/10 preference point system will be applied.

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of B-BBEE status level verification certificate or Sworn Affidavit to claim preference points, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.



- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2) decimals. In the event that two (2) or more bids have scored equal total points, the contract will be awarded to the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.

6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture oncology medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.

Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability.**

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;



- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1)(b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of such licence must be submitted by the bidder offering the product;
- The bidder offering a product must submit a **certified copy** of the licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant;
- The reference price as published by National Department of Health has not been exceeded (if applicable);
- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in these Special Requirements and Conditions of Contract.

7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.



8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature. Resolution/Authority to sign bid;
- Bid/File Index;
- SBD 1: Invitation to bid;
- PBD 4.1: Contact Details of Bidder;
- Tax Clearance Certificate (Current & Valid);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- PBD9: Directors: Categorisation by race, gender and disability;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- SBD 4: Declaration of interest;
- SBD5: The National Industrial Participation Programme;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;



- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance;
- Proof of company cedings, mergers and name changes;
- Licence to manufacture or import (in the name of the bidder), including all annexures. Certified copies required;
- Licence to manufacture medicines,including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant). Certified copies required;
- Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies
Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered.
Note: All PI`s must be marked with the relevant item number and be sorted and filed/submitted in numerical order;
- Proof of sample submission;
- Bidder`s item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals).

9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.



Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

Do not use binding methods like coil, comb, wire velobind, screw binding etc.

Pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file.

Tie bid documents in parcels using string or rope that can be easily untied for filing purposes.

Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the price quoted for a product (line item) on the Excel Bid Response Document is for the unit pack specified. No conversion factors will be applied.

10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.



11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

12. FRONTING

The National Department of Health supports the spirit of Broad Based Black Economic Empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period. This may include site visits to assess whether an item is manufactured at the site specified in the bid and the site complies with quality criteria.



14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary. Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.

15. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Civitas Building

242 Struben Street

Cnr Thabo Sehume Street

Pretoria

0002

Please use the following e-mail address for any queries relating to bidding process:

- tenders@health.gov.za



SECTION B

16. CONTRACT PERIOD

The contract period shall be for period 1 July 2020 to 30 June 2022.

17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are:

National Departments:

Provincial Departments:

- Eastern Cape;
- Free State;
- Gauteng;
- KwaZulu-Natal;
- Limpopo.
- Mpumalanga;
- Northern Cape;
- North West;
- Western Cape; and

Other Institutions

- Nelson Mandela Childrens' Hospital

18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in inability to process payment for goods.



19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item.

In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.



The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand. The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10

Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%



20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases, these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the “Medicine treatment” section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase inhibitors (Statins) e.g. simvastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

A single member of the class may be awarded.

Therapeutic class description	Members of the therapeutic class
Aromatase Inhibitors	Anastrozole 1mg tablet, 28 tablets vs Letrozole 2.5mg tablet, 28 tablets
Gonadotrophin-Releasing Hormone Analogues	Buserelin 9,9mg, injectable depot implant, single disposable applicator vs Goserelin 10.8mg injection



Therapeutic class description	Members of the therapeutic class
Serotonin (5HT3) Antagonists - Parenteral	Granisetron 1mg injection vs Ondansetron 8mg injection
Serotonin (5HT3) Antagonists - Oral	Granisetron 1mg tablet, 10 tablets vs Ondansetron 8mg tablet, 10 tablets
Bisphosphonates	Ibandronic acid 6mg injection vs Zoledronic Acid 4mg injection

21. NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.

The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award.

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the international market place.



23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:

The submission of a complete price breakdown per instructions below for all relevant products; and
Assessment of the rationality of this price breakdown by the National Department of Health.

23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the pricing schedule on the item level questionnaire. The delivered price must be divided across five components:
 - Active Pharmaceutical Ingredients (API);
 - Formulation;
 - Packaging;
 - Logistics (this includes transportation, warehousing and distribution);
 - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.



Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

Currency	Base Average Rates of Exchange Average for the period 1 March 2019 to 31 August 2019
Rand per US Dollar	14.45
Rand per Br Pound	18.37
Rand per Euro	16.22
Rand per Yuan Renminbi	2.11
Rand per Indian Rupee	0.21

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 March 2019 to 31 August 2019 using the South African Reserve Bank published rates for the specific currency.

23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.



23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 July 2020 - 31 December 2020	03 January 2021	01 February 2021
2	01 January 2021 - 30 June 2021	03 July 2021	01 August 2021
3	01 July 2021 - 31 December 2021	03 January 2022	01 February 2022

23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
0.1	01 July 2020 - 30 September 2020	03 October 2020	01 November 2020
1.1	01 January 2021 - 31 March 2021	03 April 2021	01 May 2021
2.1	01 July 2021 - 30 September 2021	03 October 2021	01 November 2021
3.1	01 January 2022 - 29 February 2022	03 April 2022	01 May 2022

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:



Review	Period for calculating adjustment average RoE post exceptional adjustment	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 October 2020 - 31 December 2020	03 January 2021	01 February 2021
2	01 April 2021 - 30 June 2021	03 July 2021	01 August 2021
3	01 October 2021 - 31 December 2021	03 January 2022	01 February 2022

23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.

24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.

25. DELIVERY AND QUANTITIES

25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.



Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur. Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.



SECTION C

26. SUPPLIER PERFORMANCE MANAGEMENT

26.1 Supplier performance management

will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, the National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
 - All transactional data relating to orders;
 - A monthly age analysis;
 - Production pipeline data and forecast including:
 - Number of units of the item available (stock on hand);
 - Number of units of the item in Quality Assurance, awaiting release;
 - Number of units of the item in the current month's production plan.
 - Status of outstanding orders.
- **Attendance of compulsory quarterly meetings**
 - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.



- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.
- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
- Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
- The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Only orders made using an official, authorised purchase order format are valid.
- Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.



- Invoices must reflect both the "proprietary name "(brand name"/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.
- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
 - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
 - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
 - industrial action;
 - challenges with manufacturing pipeline;
 - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.



- Contractors must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.
- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.
- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier will source alternative product of acceptable quality and up to the same quantity as required in terms of the contract. The substitute item will be supplied at the current price of the contracted item.
- Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
- In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

27. PACKAGING, LABELLING AND BARCODES

27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.



- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
- Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;
 - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;
 - The outer packaging must be clearly marked as a "Part Box".

27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC;
 - Registered product name (if applicable);
 - Number of units in pack;
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.



- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC;
 - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
 - Dosage form and strength;
 - Pack size;
 - Batch number;
 - Expiry date.

28. SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
 - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
 - Applications are approved by the Participating Authorities before execution of orders; and
 - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.



- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
- $A = (12 - \text{months to date of expiry}) \times 2\% \times \text{consignment value short dated product}$. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

The National Department of Health reserves the right to agree to the transfer of contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

A contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

30. THIRD PARTIES

Participating Authorities will not make a payment to or consult with a third party.

No third party is entitled to put an account of a Participating Authority on hold.

END